Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
BRCA mutations are associated with worse treatment outcomes in mCRPC
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
A multimodal liquid biopsy analysis shows promise in monitoring response to immunotherapy
A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Cancer Research
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
Can ctDNA predict outcomes in early phase trials?
Baseline and on-treatment changes in ctDNA may provide an early indication of response to experimental therapies
How to predict long-term survival to assess eligibility for phase I trials?
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Machine learning may help to uncover new immunotherapy targets
A study proposes a model that is able to learn broad aspects of cancer–immune interactions from early phase trial data
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Wider implementation of precision oncology is still challenging
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field